Hepatoprotective Properties of New Xymedon Derivatives with a Modified Structural Moiety.

We studied the hepatoprotective properties of new modifications of the Russian drug, the regeneration stimulator Xymedon (1,2-dihydro-4,6-dimethyl-1-(2-hydroxyethyl)-pyrimidin-2-one) (1): 1,2-dihydro-4,6-dimethyl-(1-(2-((hydroxyethyl)amino)ethyl)-pyrimidin-2-one (2) and 1,2-dihydro-4,6-dimethyl-1-propyl-pyrimidin-2-one (3). First, cytotoxicity and cytoprotective effects of the compounds were assessed on Chang Liver, HepG2, and WI-38 human cell lines, and then, hepatoprotective activity in vivo was evaluated on the model of toxic CCl4-induced liver damage in Wistar rats. Compounds (2) and (3) exhibited cytoprotective properties: they increased cell viability against the background of d-galactosamine treatment and reduced the morphological signs of liver damage caused by CCl4. Compound (3) had significantly higher cytotoxicity. Of the two modifications, compound (2) is more promising for further work.